WHAT HAPPENED
On March 20, 2026, FTC Chairman Andrew N. Ferguson announced the creation of a dedicated Healthcare Task Force designed to coordinate the agency's enforcement and advocacy efforts across the healthcare sector[1][3]. The task force will combine antitrust and consumer protection enforcement under a single initiative, breaking down internal silos to address what Chairman Ferguson described as consolidation and anticompetitive conduct driving higher prices, lower quality, and reduced innovation in healthcare markets[1].
WHO'S INVOLVED
The task force draws members from multiple FTC divisions: the Bureaus of Competition and Consumer Protection, the Bureau of Economics, and the Offices of Policy Planning, Technology, and General Counsel[3][10]. It will be co-chaired by representatives from the Bureaus of Competition and Consumer Protection, with at least three members from each bureau and one each from the offices mentioned[10]. The task force will also expand to include external partners such as the Department of Health and Human Services and the Department of Justice[1][3]. The initiative meets monthly and reports to the Chairman quarterly[9].
CONTEXT & TIMELINE
The task force aligns with President Trump's February 25, 2025 Executive Order directing federal agencies to create "a more competitive, innovative, affordable, and higher quality healthcare system"[1][7]. The FTC's recent enforcement record demonstrates momentum: it secured the abandonment of the Alcon-Lensar merger (~$356 million), extracted $145 million in consumer redress from health insurance plan providers, and negotiated a "landmark settlement" with pharmacy benefit manager Express Scripts in February 2026[9][11].
WHY IT'S NEWSWORTHY
The task force formalization signals an aggressive escalation of healthcare enforcement, combining consumer protection and antitrust strategies to increase enforcement effectiveness[5]. It specifically prioritizes pharmacy benefit manager transparency, anticompetitive mergers, patent practices, and deceptive marketing, while planning "horizon-scanning" for emerging issues like telehealth, artificial intelligence, and health data platforms[2][5]. Industry observers view this as a signal that regulatory scrutiny will intensify rather than plateau[2].